Precipio, Inc. (PRPO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Precipio, Inc. is a healthcare biotechnology company focused on cancer diagnostics, operating CLIA-certified laboratories in New Haven, Connecticut, and Omaha, Nebraska. The company develops diagnostic products and services to address cancer misdiagnoses. This report covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Net Sales | $4.44 million | $7.87 million | $6.35 million |
| Gross Profit | $1.72 million | $2.64 million | $2.12 million |
| Gross Margin | 39% | 33% | 33% |
| Operating Loss | $(1.21) million | $(3.28) million | $(5.32) million |
| Net Loss | $(1.22) million | $(3.30) million | $(5.32) million |
| Cash and Equivalents | $1.28 million (as of June 30, 2024) | ||
| Working Capital | $(1.23) million deficit (as of June 30, 2024) | ||
| Long-Term Debt | $0.34 million total (includes $0.25M new loan) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 26% in Q2 2024 and 24% YTD compared to 2023. This was driven by a significant increase in diagnostic testing case volume (92% increase in Q2 cases), partially offset by a decline in product revenue.
- Expense Reduction: Operating expenses decreased by $0.7 million in Q2 and $1.5 million YTD compared to the prior year, primarily due to reduced personnel costs in sales and marketing and lower R&D supply costs.
- Improved Cash Flow: Net cash used in operating activities improved significantly to $0.17 million YTD 2024 compared to $2.78 million YTD 2023, aided by a $1.1 million increase in accrued expenses (largely due to CHC funding assistance) and non-cash adjustments.
- Debt Financing: In May 2024, the company secured a new $250,000 business loan with a 20% interest rate to support liquidity.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern for the next 12 months due to recurring losses, a working capital deficit, and an accumulated deficit of $101.4 million. Continued operations depend on raising additional financing.
- Change Healthcare Cyberattack: A February 2024 cyberattack on billing vendor Change Healthcare (CHC) disrupted Precipio's billing and reimbursement processes. The company received approximately $1.1 million in temporary funding assistance from CHC, recorded as a liability. Management expects billing to normalize in Q3 2024, but delays have impacted cash collections.
- Capital Resources: The company has an "At-The-Market" (ATM) sales agreement with AGP, with approximately $3.7 million remaining availability for future stock sales.
- Legal Proceedings: The company is delinquent on payments to certain vendors who have threatened legal action. There are also ongoing routine legal proceedings incidental to the business.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $1.28 million cash balance against the $1.23 million working capital deficit and upcoming debt obligations.
- CHC Recovery: Monitor the restoration of Change Healthcare systems and the actual collection of the $0.4 million in receivables delayed by the cyberattack.
- Financing Progress: Track the utilization of the remaining $3.7 million ATM facility and the terms of any new debt or equity raises required to address the going concern warning.
- Vendor Relations: Assess the status of delinquent accounts payable and potential legal risks from suppliers.
- Revenue Mix: Evaluate the sustainability of the 92% increase in case volume versus the decline in product revenue and average price per case.